explore -WSS

explore

author：focus 2025-09-27 11:58:18 - browse：8266

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： In areas with more Black doctors, Black people live longer

hotspot

WSS

H5N1 bird flu: what we're starting to learn about infection in cows

Paxlovid study fails to answer questions over benefit for broader groups

Telehealth startups turn to complex chronic diseases

H5N1 communication has been strictly for the birds

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Researchers on aging grapple with how to calculate biological age

hotspot

explore

hotspot

Medical records are filled with copy

Study: AI not yet building 'n

Guidelines to prevent youth baseball injuries need more muscle

#NeedHerScience: shining a light on gender disparities in medicine

Novavax promises a turnaround & Lilly roils the obesity market

Elevance, private equity launch primary care company

Cancer drug shortages should be causing more outrage

Weight bias in eating disorder treatment complicated by new weight loss drugs

Tori Bowie and the unacceptable rates of Black maternal death

Readout LOUD podcast: brain research, obesity drug sales, Novartis

explore

Study: AI not yet building 'n

Why we need to separate burnout from moral injury in health care

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Why are elite athletes different? Take a look at their microbes

H5N1 bird flu: what we're starting to learn about infection in cows

Study: AI not yet building 'n

hotspot

hotspot

hotspot

knowledge